OR WAIT null SECS
This compilation allows readers to adjust their thinking to appreciate the full impact certain select technologies will make on the industry by 2026.
The testing of new convecdiff membranes shows this material to be well suited for lab- and commercial-scale bind-and-elute applications.
Cautiously setting aside pandemic practices, pharma workers appear ready for flux, change, evolution, and expanding molecular diversity.
Biologic drug development requires relevant bioassays to measure and help predict cellular response.
Affinity chromatography resins must perform well under mild elution conditions yet withstand robust cleaning and sanitization protocols.
Efforts to optimize the ideal blend of technology and best practices that are needed to protect and deliver time- and temperature-sensitive biologic therapies, vaccines, and cell and gene therapies continue to evolve.
Health crises, political tension, and budget concerns were major challenges.
January 02, 2023
January 01, 2023
Politics and drug shortages will continue to impact FDA and drug manufacturers in 2023.
A CCS provides significant benefits to the industry and helps with holistically understanding contamination controls, says Siegfried Schmitt, vice president, Technical at Parexel.
Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”
Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.
December 22, 2022
She also mentioned the Clinical Trials Regulation and the Clinical Trials Information System (CTIS) launching at the same time to help energize the clinical research area of the EU.
In addition, the Clinical Trials Regulation is set to become a single-entry point for sponsors and regulators in January 2023 for the submission and assessment of all new clinical trials.